SCHEMBL26123683

SCHEMBL26123683

C#CCCCCCCCN1CCC(NC(=O)c2n[nH]cc2NC(=O)c2c(Cl)cccc2Cl)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK9 P50750 5/20 0.44
▸ CDK5 Q00535 3/20 0.44
▸ CCNT1 O60563 2/20 0.44
▸ CDK5R1 Q15078 2/20 0.44
▸ CDK14 O94921 11/20 0.42
▸ CCNY Q8ND76 11/20 0.42
▸ CHRM2 P08172 4/20 0.41
▸ CHRM1 P11229 4/20 0.41
▸ CHRM3 P20309 4/20 0.41
▸ CDK4 P11802 2/20 0.41
▸ CDK2 P24941 2/20 0.41
▸ CASK O14936 1/20 0.41
▸ CDKL5 O76039 1/20 0.41
▸ CCNB2 O95067 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ CCNB1 P14635 1/20 0.41
▸ CCNA2 P20248 1/20 0.41
▸ MAK P20794 1/20 0.41
▸ CDK11B P21127 1/20 0.41
▸ CCND1 P24385 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31664698 1.00 CDK9 (0.44) CDK9CDK5CCNT1CDK5R1CDK14
SCHEMBL30689600 1.00 CDK9 (0.44) CDK9CDK5CCNT1CDK5R1CDK14
SCHEMBL30689623 1.00 CDK9 (0.44) CDK9CDK5CCNT1CDK5R1CDK14
SCHEMBL30689624 0.99 CDK5 (0.45) CDK9CDK5CCNT1CDK5R1CDK14
SCHEMBL30689622 0.93 CDK5 (0.47) CDK9CDK5CCNT1CDK5R1CDK14
SCHEMBL8262979 0.86 CDK5 (0.48) CDK9CDK5CCNT1CDK5R1CDK14
SCHEMBL8212911 0.85 CCNT1 (0.48) CDK9CDK5CCNT1CDK5R1CDK14
SCHEMBL29256732 0.84 DRD2 (0.53) CDK9CDK5CCNT1CDK5R1CDK14
SCHEMBL24757744 0.84 CDK14 (0.49) CDK9CDK5CCNT1CDK5R1CDK14
SCHEMBL8262582 0.83 CDK5 (0.46) CDK9CDK5CCNT1CDK5R1CDK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236607-A1 CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF OHIO STATE INNOVATION FOUNDATION 2025-07-24 — — US disclosed
EP-4499148-A1 CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF Ohio State Innovation Foundation (US) 2025-02-05 — — EP disclosed
WO-2023192534-A1 CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236607-A1 CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF CDK9, CDK19, CDKL2 CDK9 1/4885CDK5 20/4885CCNT1 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback